Search

Background and aims Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical manifestations. Here, we present 150 patients with SLE attending our clinic between January and November 2016. Methods Demographics, clinics, laboratory findings, Systemic Lupus Erythematous Disease Activity Index (SLEDAI), Systemic Lupus International Clinics (SLICC)/American College of Rheumatology (ACR) damage index scores and treatments were analysed. Diagnosis was confirmed with 1997 ACR or 2012 SLICC classifications. Chi-squared or Fisher’s exact tests were used for statistical analysis. Results General characteristics are presented in Table 1. Clinics are presented in Table 2. Treatments patients ever received are presented in Table 3. Conclusions SLICC damage was positive in patients receiving pulse steroids (57%), cyclophosphamide (51%), rituximab (73%). In long term, 3 (2%) patients had pulmonary hypertension, 21 (14%) had avascular necrosis, 6 (4%) had malignancy. SLE is an autoimmune disease requiring multi-faceted approach.